Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DB34JE
|
|||
| Drug Name |
GSK4532990
|
|||
| Indication | Non-alcoholic steatohepatitis [ICD-11: DB92.1; ICD-10: K75.8; ICD-9: 571.8] | Phase 2 | [1] | |
| Company |
GlaxoSmithKline
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 17-beta-hydroxysteroid dehydrogenase 13 (HSD17B13) | Target Info | Silencer | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05583344) 17 beta-Hydroxysteroid Dehydrogenase Type 13 Minimization for the Treatment of NASH (HORIZON): A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in Adults With Pre-Cirrhotic Nonalcoholic Steatohepatitis. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Arrowhead Pharmaceuticals | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.